JP2023063189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023063189A5 JP2023063189A5 JP2021179359A JP2021179359A JP2023063189A5 JP 2023063189 A5 JP2023063189 A5 JP 2023063189A5 JP 2021179359 A JP2021179359 A JP 2021179359A JP 2021179359 A JP2021179359 A JP 2021179359A JP 2023063189 A5 JP2023063189 A5 JP 2023063189A5
- Authority
- JP
- Japan
- Prior art keywords
- flt3
- cancer
- crenolanib
- pharmaceutical composition
- tyrosine kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163270887P | 2021-10-22 | 2021-10-22 | |
| US63/270,887 | 2021-10-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023063189A JP2023063189A (ja) | 2023-05-09 |
| JP2023063189A5 true JP2023063189A5 (enExample) | 2024-10-08 |
Family
ID=86056882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179359A Pending JP2023063189A (ja) | 2021-10-22 | 2021-11-02 | 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ |
Country Status (3)
| Country | Link |
|---|---|
| US (3) | US11857546B2 (enExample) |
| JP (1) | JP2023063189A (enExample) |
| WO (1) | WO2023069152A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023063189A (ja) | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ |
| WO2025132479A1 (en) * | 2023-12-18 | 2025-06-26 | Institut National de la Santé et de la Recherche Médicale | Flt3 inhibitor for modulating macrophages polarization |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2403876A (en) | 1943-01-22 | 1946-07-09 | Friedrich F Nord | Glycol esters and method of producing same |
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| CA2303830A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| NZ571898A (en) | 2003-06-24 | 2010-01-29 | Pfizer Prod Inc | Reaction of 2-chloro-8-benzyloxyquinoline with 2-nitrophenylamine in the presence of 1,2-bis(diphenylphosphino)ethane (dppe), palladium catalyst and a base |
| BR112015016282A2 (en) * | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| HK1257195A1 (zh) * | 2016-11-02 | 2019-10-18 | 安罗格制药有限责任公司 | 用於治疗flt3突变型增殖性疾患相关突变的克莱拉尼 |
| JP2023063189A (ja) | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ |
-
2021
- 2021-11-02 JP JP2021179359A patent/JP2023063189A/ja active Pending
-
2022
- 2022-06-02 US US17/830,682 patent/US11857546B2/en active Active
- 2022-06-02 WO PCT/US2022/031912 patent/WO2023069152A1/en not_active Ceased
-
2023
- 2023-11-20 US US18/513,888 patent/US12295948B2/en active Active
-
2025
- 2025-01-15 US US19/021,964 patent/US20250161293A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022071099A5 (enExample) | ||
| JP2019532011A5 (enExample) | ||
| JP2014097929A5 (enExample) | ||
| KR101738063B1 (ko) | 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법 | |
| WO2023190748A1 (ja) | 腫瘍治療用医薬組成物 | |
| CA3079010A1 (en) | Formulations comprising 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazab icyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | |
| JP2014065696A5 (enExample) | ||
| JP2019510746A5 (enExample) | ||
| JP2013509444A (ja) | がんの治療方法及び治療用組成物 | |
| TW201908317A (zh) | 使用parp抑制劑、替莫唑胺及/或放射療法的組合治療癌症 | |
| US20250032497A1 (en) | Combination therapies | |
| JP2023063189A5 (enExample) | ||
| JP2011503063A5 (enExample) | ||
| US10463658B2 (en) | Method of inhibiting FLT3 kinase | |
| CN118338904A (zh) | KRAS G12D抑制剂与PI3Ka抑制剂的组合及相关治疗方法 | |
| CN111249282B (zh) | 癌症疗法 | |
| CN107438437A (zh) | 用于癌症的新治疗 | |
| US20230056604A1 (en) | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer | |
| JP2016106092A (ja) | 組合せ | |
| Sadaba et al. | Comparative pharmacology of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia | |
| TWI803541B (zh) | 對於蛋白激酶具抑制活性之噻吩并[3,2-d]嘧啶化合物 | |
| JP2016104765A (ja) | 組合せ | |
| JP2022549272A (ja) | Ｅｇｆｒ阻害剤とｃｄｋ４／６阻害剤の組み合わせを用いたｅｇｆｒ変異に関連する癌の治療 | |
| JP5881671B2 (ja) | チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 | |
| JP2019163306A (ja) | ３−［（３−｛［４−（４−モルホリニルメチル）−１ｈ−ピロール−２−イル］メチレン｝−２−オキソ−２，３−ジヒドロ−１ｈ−インドール−５−イル）メチル］−１，３−チアゾリジン−２，４−ジオンとｅｇｆｒチロシンキナーゼ阻害剤との新しい併用 |